AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda

AstraZeneca has stopped a phase 3 trial of volrustomig in lung cancer based on interim efficacy data, narrowing the opportunity for a bispecific designed to replace current immune checkpoint inhibitors.